Please login to the form below

Not currently logged in

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

FDA smartphone regulation could stifle innovation

US House Republicans issue warning on guidance and call for more information

Mobile deviceUS politicians have called on the Food and Drug Administration (FDA) to provide more information about the way it intends to regulate medical smartphone apps, warning the regulator's draft guidance risks holding back innovation in the sector.

Republican leaders of the House Energy and Commerce Committee wrote to FDA commissioner Margaret Hamburg earlier this month with a series of questions, first among them: when will the FDA issue final guidance for medical apps?

The Committee, whose broad oversight includes telecommunications, food and drug safety and health services, is currently looking at how current legislation is applied to smartphone, tablet and mobile application manufacturers.

The FDA began seeking public input on its planned approach for regulating mobile medical apps as medical devices in July 2011, launching what was meant to be a three-month consultation on its draft guidance for the technology.

The regulator proposed then that it would oversee what it terms 'mobile medical apps' - those it judges could cause patients harm if they don't work as intended – but it's a potentially wide category of apps that could include disease calculator and patient data apps, two popular categories.

In its letter to the FDA, the House Committee also voiced its concern that rules on the mobile technology could encompass 'actual use' and not just 'intended use', something they say “could affect the growth and innovation in this market”.

The Committee wants to know:

• When will the FDA issue final or updated guidance for mobile medical applications designed for use on smartphones or other mobile computing devices

• Has the FDA discussed, prepared or analysed the effect of the medical device tax, mandated by the Patient Protection and Affordable Care Act, on smartphones (as well as tablets or similar devices)?

• Will the actual use of a smartphone, tablet or app be a factor in whether the FDA chooses to regulate the device or app as a medical device?

• How many mobile medical apps have sought approval from the FDA before entering the market? How many mobile medical apps have been subject to oversight by the FDA after introduction to the market?

• How many apps have either been changed or removed from the market by FDA oversight, and why?

While the FDA has approved a device that transforms an iPhone into a heart monitor and a Bluetooth-enabled blood glucose monitor, both the regulator and pharma have so far shied away from getting the expanding range of industry mobile apps certified as medical devices.

12th March 2013

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...